Melanoma

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of…

3 years ago